| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00262-017-2036-5 |
| P698 | PubMed publication ID | 28689360 |
| P50 | author | Thierry Fest | Q56997299 |
| Mikael Roussel | Q57070336 | ||
| Jonathan M. Irish | Q41645616 | ||
| P2093 | author name string | Karin Tarte | |
| Cedric Menard | |||
| Faustine Lhomme | |||
| P2860 | cites work | Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells | Q57279527 |
| The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. | Q53153100 | ||
| The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. | Q53546594 | ||
| Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum | Q24594356 | ||
| Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards | Q26744395 | ||
| Role of the tumor microenvironment in mature B-cell lymphoid malignancies | Q26748775 | ||
| Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment | Q26799126 | ||
| Clarifying Tissue Clearing | Q26799523 | ||
| A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans | Q27310807 | ||
| Myeloid-derived suppressor cells as regulators of the immune system | Q28131637 | ||
| Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma | Q28281028 | ||
| Stromal gene signatures in large-B-cell lymphomas | Q28302107 | ||
| The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment | Q28388630 | ||
| Coordinated regulation of myeloid cells by tumours | Q28395157 | ||
| Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 | ||
| Methods for discovery and characterization of cell subsets in high dimensional mass cytometry data | Q30952528 | ||
| Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. | Q30966717 | ||
| Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era | Q33558130 | ||
| An Immune Atlas of Clear Cell Renal Cell Carcinoma | Q33649707 | ||
| Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice | Q33721765 | ||
| CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer | Q33897765 | ||
| Tumor-associated macrophages and survival in classic Hodgkin's lymphoma | Q33962334 | ||
| Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages | Q34044797 | ||
| Coordinated regulation of NK receptor expression in the maturing human immune system. | Q34476273 | ||
| Mass Cytometry: Single Cells, Many Features | Q34525494 | ||
| Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma | Q34627838 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. | Q34882773 | ||
| Clinical recovery from surgery correlates with single-cell immune signatures | Q35100326 | ||
| Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry | Q35105312 | ||
| Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma | Q35688965 | ||
| Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma | Q35717862 | ||
| Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma | Q35902813 | ||
| Computational flow cytometry: helping to make sense of high-dimensional immunology data | Q36056350 | ||
| Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas | Q36090011 | ||
| Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. | Q36191426 | ||
| Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). | Q36206949 | ||
| DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. | Q36226664 | ||
| Myeloid derived suppressor cells in human diseases | Q36338349 | ||
| Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study | Q36354265 | ||
| Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. | Q36625499 | ||
| Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial | Q36715971 | ||
| Multiparameter analysis of stimulated human peripheral blood mononuclear cells: A comparison of mass and fluorescence cytometry. | Q36730456 | ||
| Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans | Q36761567 | ||
| The 2016 revision of the World Health Organization classification of lymphoid neoplasms | Q36920426 | ||
| Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy | Q36963592 | ||
| M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma | Q37134780 | ||
| Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species | Q37293474 | ||
| Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. | Q37317367 | ||
| B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. | Q37348263 | ||
| The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma | Q37507473 | ||
| Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry | Q37569278 | ||
| Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells. | Q37623812 | ||
| Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes | Q37706368 | ||
| Myeloid-derived suppressor cells in cancer patients: a clinical perspective. | Q37981536 | ||
| Tumor-associated macrophages: functional diversity, clinical significance, and open questions | Q38105286 | ||
| The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. | Q38131611 | ||
| The tumour microenvironment in B cell lymphomas | Q38227748 | ||
| Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma | Q38313124 | ||
| The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium | Q38572605 | ||
| Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance | Q38609223 | ||
| Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. | Q38629590 | ||
| The role of myeloid cells in cancer therapies | Q38875474 | ||
| Characterizing cell subsets using marker enrichment modeling | Q38991987 | ||
| CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. | Q38992830 | ||
| Dendritic cells in hematological malignancies | Q39033399 | ||
| Tumour-associated macrophages as treatment targets in oncology. | Q39100693 | ||
| Imaging Mass Cytometry | Q39119302 | ||
| Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties | Q39192585 | ||
| 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity | Q39715226 | ||
| M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. | Q39870660 | ||
| Mapping the human DC lineage through the integration of high-dimensional techniques. | Q40225787 | ||
| Single-cell trajectory detection uncovers progression and regulatory coordination in human B cell development | Q40297899 | ||
| Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study | Q40338899 | ||
| Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity | Q40372686 | ||
| Myeloid-Derived Suppressor Cells | Q40385399 | ||
| T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells | Q40638845 | ||
| Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry | Q40680881 | ||
| New insights into the multidimensional concept of macrophage ontogeny, activation and function. | Q40866271 | ||
| Single-cell mass cytometry analysis of human tonsil T cell remodeling by varicella zoster virus | Q42204988 | ||
| Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma | Q42591459 | ||
| Tumor-associated macrophages in diffuse large B-cell lymphoma | Q42940545 | ||
| Beyond the age of cellular discovery. | Q45955864 | ||
| High-dimensional analysis of the murine myeloid cell system. | Q45956087 | ||
| Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). | Q46525283 | ||
| High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. | Q46845329 | ||
| A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. | Q46972244 | ||
| Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells | Q47600079 | ||
| Single cell analysis of human tissues and solid tumors with mass cytometry. | Q48368350 | ||
| Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. | Q50647447 | ||
| Mapping the Diversity of Follicular Helper T Cells in Human Blood and Tonsils Using High-Dimensional Mass Cytometry Analysis. | Q50729091 | ||
| Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. | Q51037023 | ||
| Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. | Q51660178 | ||
| Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. | Q52808766 | ||
| Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow. | Q52881850 | ||
| Mass Cytometry of the Human Mucosal Immune System Identifies Tissue- and Disease-Associated Immune Subsets. | Q53095382 | ||
| The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. | Q53141508 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 1103-1111 | |
| P577 | publication date | 2017-07-08 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Regulatory myeloid cells: an underexplored continent in B-cell lymphomas | |
| P478 | volume | 66 |
| Q64070430 | Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients |
| Q90254095 | HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma |
| Q90101887 | Hide or defend, the two strategies of lymphoma immune evasion: potential implications for immunotherapy |
| Q90307119 | Human monocytic myeloid-derived suppressor cells impair B-cell phenotype and function in vitro |
| Q92736066 | Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer |
| Q92541764 | Ping-Pong-Tumor and Host in Pancreatic Cancer Progression |
| Q57138311 | Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies |
| Q92821367 | Targeting the Tumor Microenvironment of Leukemia and Lymphoma |
| Q54957513 | The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas. |
Search more.